Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with...

Area of Science:

• Cardiovascular Research
• Endocrinology
• Nephrology

Background:

• Endoglin, a glycoprotein, is crucial for cardiovascular homeostasis.
• Soluble endoglin (sEng), an antiangiogenic form, is elevated in hypertension, diabetes, and hypercholesterolemia, indicating endothelial damage.
• sEng is a potential biomarker for endothelial dysfunction in hypertensive patients.

Purpose of the Study:

• To evaluate the impact of different antihypertensive regimens on soluble endoglin (sEng) levels.
• To compare the efficacy of perindopril versus other antihypertensive treatments in reducing sEng in hypertensive patients.
• To assess the relationship between sEng levels and endothelial damage markers.

Main Methods:

• 323 patients were analyzed: normotensive controls, hypertensive patients on monotherapy (beta-blockers, calcium channel blockers, diuretics), and hypertensive patients on perindopril.
• Plasma sEng levels were quantified using validated methods.
• Correlation analysis was performed between sEng levels and established endothelial damage markers.

Main Results:

• Hypertensive patients treated with perindopril exhibited significantly lower plasma sEng levels (4.73±1.39) compared to those on other antihypertensive regimens (5.63±2.33, p<0.01).
• The study identified a significant difference in sEng levels between treatment groups, indicating varying effects on endothelial markers.
• Perindopril demonstrated a superior effect in reducing sEng compared to beta-blockers, calcium channel blockers, and diuretics.

Conclusions:

• Chronic perindopril treatment is associated with reduced plasma sEng levels in hypertensive patients.
• Perindopril appears more effective than other antihypertensive regimens in lowering sEng, suggesting a potential benefit for endothelial health.
• These findings highlight perindopril's potential role in managing endothelial dysfunction in hypertension.